Sensitivity of Dried Blood Spot Testing for Detection of Congenital Cytomegalovirus Infection.
Sensitivity of Dried Blood Spot Testing for Detection of Congenital Cytomegalovirus Infection.
复制标题
DOI:
10.1001/jamapediatrics.2020.5441
复制
发表时间:
2021-03-01
期刊:
影响因子:
26.1
通讯作者:
Schleiss MR
中科院分区:
文献类型:
--
作者:
Dollard SC;Dreon M;Hernandez-Alvarado N;Amin MM;Wong P;Lanzieri TM;Osterholm EA;Sidebottom A;Rosendahl S;McCann MT;Schleiss MR
This cohort study assesses the sensitivity of dried blood spots polymerase chain reaction for newborn screening for congenital cytomegalovirus infection using saliva as the reference standard for screening, followed by collection of a urine sample for confirmation of congenital infection What is the sensitivity of polymerase chain reaction testing for congenital cytomegalovirus deployed on dried blood spots obtained for universal newborn screening using current best methods? This cohort study of 12 554 newborns screened in a multisite study in Minnesota included 56 (4.5 per 1000) with confirmed congenital cytomegalovirus infection. The sensitivity of dried blood spots polymerase chain reaction testing was 85.7% with results of 2 laboratory results combined, which is substantially higher than reported in past studies. The relatively high sensitivity of dried blood spots in the interim analysis of this study suggests their potential usefulness for universal cytomegalovirus screening as DNA extraction and polymerase chain reaction methodologies continue to improve. The sensitivity of dried blood spots (DBS) to identify newborns with congenital cytomegalovirus (cCMV) infection has not been evaluated in screening studies using the current, higher-sensitivity methods for DBS processing. To assess the sensitivity of DBS polymerase chain reaction (PCR) for newborn screening for cCMV infection using saliva as the reference standard for screening, followed by collection of a urine sample for confirmation of congenital infection. This population-based cohort study took place at 5 newborn nurseries and 3 neonatal intensive care units in the Minneapolis/Saint Paul area in Minnesota from April 2016 to June 2019. Newborns enrolled with parental consent were screened for cCMV using DBS obtained for routine newborn screening and saliva collected 1 to 2 days after birth. Dried blood spots were tested for CMV DNA by PCR at both the University of Minnesota (UMN) and the US Centers for Disease Control and Prevention (CDC). Saliva swabs were tested by CMV DNA PCR at the UMN laboratory only. Newborns who screened positive by saliva or DBS had a diagnostic urine sample obtained by primary care professionals, tested by PCR within 3 weeks of birth. Analysis began July 2019. Detection of CMV from a saliva swab using a PCR assay. Number of children with urine-confirmed cCMV and the proportion of them who were CMV positive through DBS screening. Of 12 554 individuals enrolled through June 2019 (of 25 000 projected enrollment), 56 newborns were confirmed to have cCMV (4.5 per 1000 [95% CI, 3.3-5.7]). Combined DBS results from either UMN or CDC had a sensitivity of 85.7% (48 of 56; 95% CI, 74.3%-92.6%), specificity of 100.0% (95% CI, 100.0%-100.0%), positive predictive value (PPV) of 98.0% (95% CI, 89.3%-99.6%), and negative predictive value (NPV) of 99.9% (95% CI, 99.9%-100.0%). Dried blood spot results from UMN had a sensitivity of 73.2% (95% CI, 60.4%-83.0%), specificity of 100.0% (100.0%-100.0%), PPV of 100.0% (95% CI, 91.4%-100.0%), and NPV of 99.9% (95% CI, 99.8%-99.9%). Dried blood spot results from CDC had a sensitivity of 76.8% (95% CI, 64.2%-85.9%), specificity of 100.0% (95% CI, 100.0%-100.0%), PPV of 97.7% (95% CI, 88.2%-99.6%), and NPV of 99.9% (95% CI, 99.8%-99.9%). Saliva swab results had a sensitivity of 92.9% (52 of 56; 95% CI, 83.0%-97.2%), specificity of 99.9% (95% CI, 99.9%-100.0%), PPV of 86.7% (95% CI, 75.8%-93.1%), and NPV of 100.0% (95% CI, 99.9%-100.0%). This study demonstrates relatively high analytical sensitivity for DBS compared with previous studies that performed population-based screening. As more sensitive DNA extraction and PCR methods continue to emerge, DBS-based testing should remain under investigation as a potential low-cost, high-throughput option for cCMV screening.
登录
查看更多内容
影响因子:
2.5
作者:
Meyer, Lucy;Sharon, Bazak;Schleiss, Mark R.
通讯作者:
Schleiss, Mark R.
影响因子:
3.7
作者:
Nagel, Angela;Dimitrakopoulou, Emmanouela;Ueberla, Klaus
通讯作者:
Ueberla, Klaus
影响因子:
120.7
作者:
Boppana, Suresh B.;Ross, Shannon A.;Fowler, Karen B.
通讯作者:
Fowler, Karen B.
影响因子:
4.2
作者:
Mei, JV;Alexander, JR;Hannon, WH
通讯作者:
Hannon, WH
影响因子:
3.7
作者:
Cannon, Michael J.;Stowell, Jennifer D.;Dollard, Sheila C.
通讯作者:
Dollard, Sheila C.